피부암 진단 시장 규모, 점유율, 동향 분석 보고서 : 암 유형별, 검사 유형별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Melanoma, Non-Melanoma), By Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests) By End-use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,833,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,318,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,288,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

피부암 진단 시장 요약

세계의 피부암 진단 시장 규모는 2024년 95억 8,000만 달러로 평가되었고, 2033년까지 156억 7,000만 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 연평균 복합 성장률(CAGR) 5.7%를 나타낼 전망입니다. 인공지능(AI)의 통합, 기술 진보 및 비침습적 진단법에 대한 환자 선호가 성장을 이끌고 있습니다.

또한 피부암에 대한 인식이 높아지고 AI 기반 진단 도구의 진보, 조기 발견을 촉진하는 대처, 특히 햇빛에 노출되는 지역에서의 발병률의 상승이 시장 성장을 견인할 것으로 예측됩니다. 예를 들어, 미국암협회에 따르면 침윤성 흑색종은 전체 피부암 증례의 불과 1%를 차지하고 있으며, 2024년에는 미국에서 침윤성 흑색종의 신규 증례가 약 10만 640건, 상피내 흑색종이 약 9만 9,700건 진단되었습니다. 의료 제공업체와 기술 기업 간의 제휴는 진단의 접근성과 정확성을 향상시킴으로써 이러한 성장을 더욱 강화하고 있습니다.

또한 AI를 활용한 제품 승인 등 첨단 기술이 시장 성장을 견인하고 있습니다. 예를 들어, 2024년 1월에는 FDA가 최초의 AI 탑재 피부암 진단 도구인 DermaSensor 디바이스의 승인을 실시했습니다. 또한 DermaSensor는 흑색종, 편평상피암, 기저세포암을 포함한 피부암에 대해 정량적이고 검사 현장에서의 동정을 제공합니다. 또한 DermaSensor 장치는 병변의 세포와 세포내 특성을 확인하기 위해 인공지능(AI)을 활용한 분광법을 채용하고 있습니다.

현대의 머신러닝 기술은 분류에 유용한 패턴을 식별하기 위해 방대한 데이터 세트에 의존하며, 진단 이미지 분야는 특히 AI 조사에서 유망한 영역입니다. 게다가 피부암 검출은 임상 이미지나 더모스카피 이미지의 해석이 주관적인 성질상 AI에 있어서 특히 매력적인 검사 유형이라고 할 수 있습니다. 또한 AI 지원 진단은 많은 지역에서 부족하기 쉬운 전문의의 지식에 대한 액세스 향상과 같은 이점을 제공하여 전문의의 예약 대기 시간의 장기화를 해소합니다. AI 기반 시스템이 인간 전문가보다 높은 일관성과 정확성을 제공할 수 있는 가능성에 대해 낙관적인 관점이 퍼지고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 피부암 진단 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 피부암 진단 시장 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 피부암 진단 시장 : 암 유형별 추정 및 동향 분석

• 세계의 피부암 진단 시장 : 암 유형별 대시보드
• 세계의 피부암 진단 시장 : 암 유형별 변동 분석
• 세계의 피부암 진단 시장, 암 유형별, 수익별
• 흑색종
• 비흑색종

제5장 피부암 진단 시장 : 검사 유형의 추정 및 동향 분석

• 세계의 피부암 진단 시장 : 검사 유형 대시보드
• 세계의 피부암 진단 시장 : 검사 유형 변동 분석
• 세계의 피부암 진단 시장, 검사 유형별, 수익별
• 피부경 검사
• 피부 생검
• 림프절 생검
• 영상 검사
• 기타

제6장 피부암 진단 시장 : 최종 용도의 추정 및 동향 분석

• 세계의 피부암 진단 시장 : 최종 사용자 대시보드
• 세계의 피부암 진단 시장 : 최종 용도 변동 분석
• 세계의 피부암 진단 시장, 최종 용도별, 수익별
• 병원 및 진료소
• 연구소
• 기타

제7장 피부암 진단 시장 : 암 유형, 검사 유형, 최종 용도별 지역 추정 및 동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 유통업체 및 채널 파트너 목록
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2024년)
  • Castle Bioscience
  • DermTech
  • bioMerieux Inc.
  • FOUNDATION MEDICINE, INC.
  • DermaSensor, Inc.
  • F Hoffmann-La Roche Ltd
  • NeoGenomics Laboratories
  • Quest Diagnostics Incorporated
  • SkylineDx
  • Abbott

KTH

영문 목차

영문목차

Skin Cancer Diagnostics Market Summary

The global skin cancer diagnostics market size was estimated at USD 9.58 billion in 2024 and is projected to reach USD 15.67 billion by 2033, growing at a CAGR of 5.7% from 2025 to 2033. The integration of artificial intelligence, technological advancements, and patient preference for non-invasive diagnostics drives the growth.

Furthermore, increased awareness about skin cancer, advancements in AI-based diagnostic tools, and initiatives promoting early detection, rising incidence, particularly in sun-exposed regions, are expected to drive the market growth. For instance, according to the American Cancer Society, invasive melanoma accounts for only 1% of all skin cancer cases, and in 2024, an estimated 100,640 new cases of invasive and 99,700 cases of in situ melanoma were diagnosed in the U.S. Partnerships between healthcare providers and tech companies further support this growth by enhancing accessibility and accuracy of diagnoses.

Furthermore, advanced technologies such as AI-enabled product approvals are driving the growth of the market. For instance, in January 2024, the FDA approved the first AI-powered skin cancer diagnostic tool, namely the DermaSensor device. Further, DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma. Also, the DermaSensor device uses artificial intelligence (AI)-powered spectroscopy in order to identify cellular and subcellular characteristics of lesions.

Modern machine learning techniques rely on extensive datasets to identify patterns useful for classification, with diagnostic imaging being a particularly promising area for AI research. Moreover, skin cancer detection, in particular, is an attractive test type for AI due to the subjective nature of clinical and dermoscopic image interpretation. Also, AI-assisted diagnosis offers advantages such as improved access to specialist expertise, which is often scarce in many regions, leading to long waiting times for specialist appointments. There is growing optimism that AI-based systems could offer greater consistency and higher accuracy than human experts.

Global Skin Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin cancer diagnostics market report based on cancer type, test type, end use, and region:

• Cancer Type Outlook (Revenue, USD Million; 2021 - 2033)
• Melanoma
• Non-Melanoma
• Test Type Outlook (Revenue, USD Million; 2021 - 2033)
• Dermatoscopy
• Skin Biopsy
• Lymph node biopsy
• Imaging Tests
• Others
• End Use Outlook (Revenue, USD Million; 2021 - 2033)
• Hospital and Clinics
• Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Cancer Type
  • 1.2.2. Test Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Scope & Assessment
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Cancer type and test type outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements
    • 3.2.1.2. Integration of artificial intelligence
    • 3.2.1.3. Patient preference for non-invasive diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Diagnostic Imaging
• 3.3. Skin Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

• 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
• 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
• 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
• 4.4. Melanoma
  • 4.4.1. Melanoma market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Non-Melanoma
  • 4.5.1. Non-Melanoma market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

• 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
• 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
• 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
• 5.4. Dermatoscopy
  • 5.4.1. Dermatoscopy market estimates and forecasts for 2021 to 2033 (USD Million)
• 5.5. Skin Biopsy
  • 5.5.1. Skin Biopsy market estimates and forecasts for 2021 to 2033 (USD Million)
• 5.6. Lymph node biopsy
  • 5.6.1. Lymph node biopsy market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Imaging Tests
  • 5.7.1. Imaging Tests market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 6. Skin Cancer Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. Global Skin Cancer Diagnostics Market: End Use Dashboard
• 6.2. Global Skin Cancer Diagnostics Market: End Use Movement Analysis
• 6.3. Global Skin Cancer Diagnostics Market by End Use, Revenue
• 6.4. Hospital and Clinics
  • 6.4.1. Hospital and Clinics market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Laboratories
  • 6.5.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Analysis market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts for 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Castle Bioscience
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. DermTech
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. bioMerieux Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. FOUNDATION MEDICINE, INC.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. DermaSensor, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. F Hoffmann-La Roche Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. NeoGenomics Laboratories
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Quest Diagnostics Incorporated
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. SkylineDx
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Abbott
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives

관련자료